Print

Ignyta Announces Submission Of IND For RXDX-101  
2/27/2014 9:56:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, today announced that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for RXDX-101, Ignyta’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications.

Help employers find you! Check out all the jobs and post your resume.

//-->